COPD
-
PAR Symposium Tackles New Approaches for Treating Patients with Chronic Cough
on
Read more: PAR Symposium Tackles New Approaches for Treating Patients with Chronic CoughThe “PAR Symposium: New Approaches to the Patient with Chronic Productive Cough” at ATS 2026 Orlando will be held from 9:15–10:45 a.m. on Tuesday. Session Chair Siri Vaeth, MSW, shared that the symposium will address the diverse causes of chronic coughs, physical and mental health symptoms that can accompany the condition, best practices for treatment,…
-
Final Clinical Year in Review Sessions Distill Impactful Data Into Pragmatic Strategies
on
Read more: Final Clinical Year in Review Sessions Distill Impactful Data Into Pragmatic StrategiesThis year’s Clinical Year in Review presentations will cover precision approaches that incorporate biologics, endotypes risk scores, and optimal treat-to-target strategies. Ayodeji Adegunsoye, MD, PhD, MSc, series co-chair, said the aim is to empower clinicians with critical, timely information that positively affects patients’ disease trajectory. The final sessions will be held from 9:15–10:45 a.m. on…
-
ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPD
on
Read more: ATS 2026 Orlando Sessions Examine Recent Insights and Unique Challenges for Treating COPDRecent reports show that chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States in 2023, with 141,733 deaths related to the disease during that year. Additionally, treatments for the disease incur annual medical costs of approximately $24 billion for adults aged 45 and older. Spyridon Fortis, MD, PhD,…
-
Bronchiectasis and COPD Lineup at ATS 2026 Orlando
on
Read more: Bronchiectasis and COPD Lineup at ATS 2026 OrlandoATS 2026 Orlando offers a robust scientific program, featuring a variety of scientific symposia, abstract presentations, and Meet the Expert sessions to examine the latest investigative insights and clinical challenges for treating bronchiectasis and COPD.